Status:

COMPLETED

IV Iron for the Anemia of Traumatic Critical Illness

Lead Sponsor:

Denver Health and Hospital Authority

Collaborating Sponsors:

National Trauma Research Institute

Conditions:

Trauma

ICU Anemia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this clinical trial is to determine whether intravenous iron supplementation of anemic, critically ill trauma patients improves anemia and reduces the need for a red blood cell transfus...

Detailed Description

Nearly all trauma patients admitted to an intensive care unit (ICU) are anemic (low red blood cell counts). Anemia is an independent risk factor for poor outcomes, including infection, impaired wound ...

Eligibility Criteria

Inclusion

  • ICU admission for trauma
  • Adults (age ≥ 18 years)
  • Anemia (hemoglobin \< 12 g/dL)
  • ≤ 72 hours from ICU admission
  • Expected ICU length of stay ≥ 7 days

Exclusion

  • Active hemorrhage requiring RBC transfusion
  • Iron overload (serum ferritin concentration ≥ 1,000 ng/mL) or any condition associated with iron overload (e.g., hemochromatosis, aceruloplasminemia
  • Chronic inflammatory conditions (e.g., systemic lupus erythematosis, rheumatoid arthritis, ankylosing spondilitis)
  • Pre-existing hematologic disorders (e.g., thalassemia, sickle cell disease, hemophilia, von Willibrand's disease, myeloproliferative disease)
  • Macrocytic anemia (mean corpuscular volume ≥ 100 fL)
  • Current use of immunosuppressive agents including corticosteroids (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone, exclusive of inhaled corticosteroids), calcinurin inhibitors (e.g., cyclosporine, tacrolimus), antimetabolites (e.g., azathioprine), or biologics (e.g., OKT3, thymoglobulin)
  • Use of recombinant human erythropoietin formulation within the prev 30 days
  • Pregnancy or lactation
  • Prohibition of RBC transfusion
  • Stay of ≥ 48 hours duration in the ICU of a transferring hospital
  • History of intolerance or hypersensitivity to either enteral or intravenous iron
  • Moribund state in which death is imminent
  • Enrollment in any other clinical trial

Key Trial Info

Start Date :

June 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2013

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT01180894

Start Date

June 1 2011

End Date

September 1 2013

Last Update

February 5 2018

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21287

2

University of Michigan Health Systems

Ann Arbor, Michigan, United States, 48103

3

NewYork Presbyterian Medical Center/Weill Cornell Medical College

New York, New York, United States, 10065

4

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19102